Zobrazeno 1 - 10
of 126
pro vyhledávání: '"José Moltó"'
Autor:
Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, Kristin Greve-Isdahl Mohn, Antonio-José Carcas-Sansuan, Esperanza Romero Rodriguez, José Moltó, Itziar Vergara Mitxeltorena, Tobias Welte, Birutė Zablockienė, Murat Akova, Ullrich Bethe, Sarah Heringer, Jon Salmanton-García, Julia Jeck, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Lena M. Biehl, Jan Grothe, Sibylle C. Mellinghoff, Julia A. Nacov, Julia M. Neuhann, Rosanne Sprute, Jesús Frías-Iniesta, Riya Negi, Colette Gaillard, Gurvin Saini, Alejandro García León, Patrick W.G. Mallon, Christine Lammens, An Hotterbeekx, Katherine Loens, Surbhi Malhotra-Kumar, Herman Goossens, Samir Kumar-Singh, Franz König, Martin Posch, Philipp Koehler, Oliver A. Cornely
Publikováno v:
International Journal of Infectious Diseases, Vol 146, Iss , Pp 107161- (2024)
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA (mRNA)-1273 (Spikevax, 100 µg). The
Externí odkaz:
https://doaj.org/article/f8eb2936f1bc47e680925b02612648b5
Autor:
Clara Duran-Castells, Anna Prats, Bruna Oriol-Tordera, Anuska Llano, Cristina Galvez, Javier Martinez-Picado, Ester Ballana, Edurne Garcia-Vidal, Bonaventura Clotet, Jose A. Muñoz-Moreno, Thomas Hanke, José Moltó, Beatriz Mothe, Christian Brander, Marta Ruiz-Riol
Publikováno v:
EBioMedicine, Vol 95, Iss , Pp 104732- (2023)
Summary: Background: Biomarkers predicting the outcome of HIV-1 virus control in natural infection and after therapeutic interventions in HIV-1 cure trials remain poorly defined. The BCN02 trial (NCT02616874), combined a T-cell vaccine with romidepsi
Externí odkaz:
https://doaj.org/article/3b80065fccfc4b748f1b0fc22a58d62a
Autor:
Alessandra Borgognone, Marc Noguera-Julian, Bruna Oriol, Laura Noël-Romas, Marta Ruiz-Riol, Yolanda Guillén, Mariona Parera, Maria Casadellà, Clara Duran, Maria C. Puertas, Francesc Català-Moll, Marlon De Leon, Samantha Knodel, Kenzie Birse, Christian Manzardo, José M. Miró, Bonaventura Clotet, Javier Martinez-Picado, José Moltó, Beatriz Mothe, Adam Burgener, Christian Brander, Roger Paredes, the BCN02 Study Group
Publikováno v:
Microbiome, Vol 10, Iss 1, Pp 1-15 (2022)
Abstract Background The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA.HIVconsv immunogen with
Externí odkaz:
https://doaj.org/article/f4eb4630f5eb4505a01baefcff14f0eb
Publikováno v:
Cancers, Vol 15, Iss 12, p 3191 (2023)
Despite the widespread use of combined antiretroviral therapy (cART) and the subsequent decrease in AIDS-defining cancers, HIV-related lymphomas remain a leading cause of morbidity and mortality in people with HIV (PWH). Diffuse large B-cell lymphoma
Externí odkaz:
https://doaj.org/article/6478caa8b45b4af7b1ebe9a850589d92
Autor:
Bruna Oriol-Tordera, Anna Esteve-Codina, María Berdasco, Míriam Rosás-Umbert, Elena Gonçalves, Clara Duran-Castells, Francesc Català-Moll, Anuska Llano, Samandhy Cedeño, Maria C. Puertas, Martin Tolstrup, Ole S. Søgaard, Bonaventura Clotet, Javier Martínez-Picado, Tomáš Hanke, Behazine Combadiere, Roger Paredes, Dennis Hartigan-O'Connor, Manel Esteller, Michael Meulbroek, María Luz Calle, Alex Sanchez-Pla, José Moltó, Beatriz Mothe, Christian Brander, Marta Ruiz-Riol
Publikováno v:
EBioMedicine, Vol 78, Iss , Pp 103956- (2022)
Summary: Background: The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individ
Externí odkaz:
https://doaj.org/article/9f3d6a37e4e5465486ac479f3e27ef6c
Autor:
José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-4 (2020)
Abstract Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).
Externí odkaz:
https://doaj.org/article/a7d2c829d4fd40eea40e824b20cfb7c0
Autor:
Beatriz Mothe, Miriam Rosás-Umbert, Pep Coll, Christian Manzardo, Maria C. Puertas, Sara Morón-López, Anuska Llano, Cristina Miranda, Samandhy Cedeño, Miriam López, Yovaninna Alarcón-Soto, Guadalupe Gómez Melis, Klaus Langohr, Ana M. Barriocanal, Jessica Toro, Irene Ruiz, Cristina Rovira, Antonio Carrillo, Michael Meulbroek, Alison Crook, Edmund G. Wee, Jose M. Miró, Bonaventura Clotet, Marta Valle, Javier Martinez-Picado, Tomáš Hanke, Christian Brander, José Moltó, The BCN02 Study Investigators
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label,
Externí odkaz:
https://doaj.org/article/488e5500178f4b47bb1f5b03a865f708
Autor:
Miriam Rosás-Umbert, Marta Ruiz-Riol, Marco A. Fernández, Marta Marszalek, Pep Coll, Christian Manzardo, Samandhy Cedeño, José M. Miró, Bonaventura Clotet, Tomáš Hanke, José Moltó, Beatriz Mothe, Christian Brander, the BCN02 study group, Susana Benet, Anuksa Llano, Javier Martinez-Picado, Sara Morón-López, Roger Paredes, Maria C. Puertas, Roser Escrig, Silvia Gel, Miriam López, Cristina Miranda, Jose Muñoz, Nuria Perez-Alvarez, Jordi Puig, Boris Revollo, Jessica Toro, Ana Maria Barriocanal, Magi Farré, Cristina Perez-Reche, Marta Valle, Juan Ambrosioni, Irene Ruiz, Cristina Rovira, Carmen Ligero, Jose M. Miro, Antonio Carrillo, Michael Meulbroek, Ferran Pujol, Jorge Saz, Nicola Borthwick, Alison Crook, Edmund G. Wee
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T
Externí odkaz:
https://doaj.org/article/7ff34c69a231482fa4c4bba2e9a493f3
Publikováno v:
Cancers, Vol 13, Iss 17, p 4366 (2021)
Despite widespread use of combined antiretroviral therapy (cART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally
Externí odkaz:
https://doaj.org/article/67b91ac8735c4c4a9f1ad4c6e39c2768
Autor:
Jose A Muñoz-Moreno, Anna Prats, José Moltó, Maite Garolera, Núria Pérez-Álvarez, Crisanto Díez-Quevedo, Cristina Miranda, Carmina R Fumaz, Maria J Ferrer, Bonaventura Clotet, TRIANT-TE Study Group
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182547 (2017)
To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment.We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot tria
Externí odkaz:
https://doaj.org/article/501d108e4e76473992822861d9577452